Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Alphwave backs long-term strategy as takeover speculation mounts

(Sharecast News) - Alphawave IP Group said on Wednesday it remained "confident" of becoming a leading player in the semiconductor sector, as takeover speculation surrounding the tech firm heightened. Shares in the chip designer, which listed on the London market in 2021, surged on Tuesday after US semiconductor giant Qualcomm said was considering making a bid.

The approach followed reports just hours earlier that fellow chip designer Arm Holdings - majority owned by Japan's SoftBank - had also been mulling a potential offer.

In a brief statement on Thursday, Alphawave acknowledge Qualcomm's expression of interest, and said it would update the market again if and when appropriate.

But it noted: "Alphawave is confident in its strategy to become a leading semiconductor company and the value this will deliver for shareholders.

"There can be no certainty that any firm offer will be made, nor as to the terms...accordingly, shareholders are advised to take no action."

Under Takeover Panel rules, Qualcomm currently has until 5pm on 29 April to either make a firm offer or walk away.

Alphawave, which is headquartered in Toronto, Canada, was co-founded in 2017 by chief executive Tony Pialis.

As at 1230 BST, the stock was down 1% at 135.10p. So far this year Alphawave shares have put on 47%.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.